Biopharma · FDA Approvals · Stock

AGIO Agios

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd …

Assets on file: mitapivat

Catalyst calendar

Dated catalysts for AGIO, including recently decided ones.

February 2027
01
Feb 2027
Feb 1, 2027
in 71 days
AGIOAgios

Recent first-hand events

Every first-hand event for AGIO, newest first.

Instant stream — events appear as soon as they are filed.
Decision-gradeMaterialNotableMinor
Nov 17, 2026
03:25 PM
AGIOAgios

mitapivat · NCT05935202 registry update

status: NOT_YET_RECRUITING → ACTIVE_NOT_RECRUITING; primary_completion: 2025-07-15 → 2028-09-30; completion: 2026-12-15 → 2029-03-30

Trial registry changeClinicalTrials.govOpen record
Nov 5, 2026
11:33 AM
AGIOAgios

Agios mitapivat sNDA PDUFA for sickle cell disease extended to Feb 1, 2027

FDA extended the PDUFA goal date for the mitapivat sNDA in sickle cell disease by three months to February 1, 2027 after classifying Agios' response to a REMS-related information request as a major amendment. The company remains launch-ready and is continuing labeling discussions with the FDA.

PDUFA date extendedSEC 8-KOpen record
Oct 28, 2026
03:20 PM
AGIOAgios

mitapivat · NCT07656415 registry update

countries: {'total_sites': 3, 'us_sites': 3} → {'total_sites': 5, 'us_sites': 5}

Trial registry changeClinicalTrials.gov
Oct 15, 2026
03:24 PM
AGIOAgios

mitapivat · NCT07055243 registry update

status: RECRUITING → ACTIVE_NOT_RECRUITING; primary_completion: 2026-06-30 → 2029-10; completion: 2027-06-30 → 2029-10

Trial registry changeClinicalTrials.govOpen record
Sep 28, 2026
03:21 PM
AGIOAgios

mitapivat · NCT07517133 registry update

countries: {'total_sites': 4, 'us_sites': 4} → {'total_sites': 5, 'us_sites': 5}

Trial registry changeClinicalTrials.gov1 update
Jul 30, 2026
10:32 AM
AGIOAgios

Agios: FDA sets Nov 1, 2026 PDUFA for mitapivat sNDA in sickle cell disease

FDA granted Priority Review and set a PDUFA goal date of November 1, 2026 for the mitapivat sNDA in sickle cell disease. The application was submitted under the accelerated approval pathway and will require a confirmatory Phase 3 trial (REIGNITE) to verify clinical benefit. This establishes a near-term regulatory decision point for a potential new indication.

PDUFA date extendedSEC 8-KOpen record
Jun 13, 2026
01:00 PM
AGIOAgios

Agios presents RISE UP Phase 3 mitapivat data at EHA 2026 plenary

Agios presented detailed 52-week RISE UP Phase 3 results at the EHA 2026 plenary session, showing statistically significant hemoglobin response (40.6% vs 2.9%) and clinically meaningful transfusion burden reduction (41.1% fewer patients transfused). Post-hoc analyses demonstrated that hemoglobin responders experienced meaningful reductions in sickle cell pain crises, hospitalizations, and fatigue, reinforcing mitapivat's anti-hemolytic profile ahead of its sNDA submission for accelerated approval.

Conference presentationCompany press release
May 12, 2026
01:31 PM
AGIOAgios

Agios submits sNDA for mitapivat accelerated approval in sickle cell disease

Agios has submitted an sNDA to FDA for accelerated approval of mitapivat in sickle cell disease. The submission follows FDA agreement on a required confirmatory trial designed to show transfusion-burden reduction. FDA filing acceptance and review timeline are expected in Q3 2026 after the 60-day filing review period.

Apr 29, 2026
10:32 AM
AGIOAgios

Agios plans mitapivat sNDA submission for sickle cell disease in Q2 2026

Agios confirmed it will submit an sNDA for mitapivat in sickle cell disease under the FDA accelerated approval pathway in the second quarter of 2026 after completing its pre-sNDA meeting with the FDA. The filing follows the company’s earlier thalassemia approvals and is positioned as the next regulatory step for the asset.

Application submittedSEC 8-KOpen record
Feb 12, 2026
11:32 AM
AGIOAgios

Agios: FDA approves AQVESME (mitapivat) for thalassemia anemia

FDA approved AQVESME (mitapivat) in December 2025 as the only medicine for anemia in adults with alpha- or beta-thalassemia regardless of transfusion burden. The product is now available in the U.S. following REMS implementation in late January 2026. This converts the regulatory path from pending to approved and launches commercial availability.

FDA approvalSEC 8-KOpen record2 updates
Jan 12, 2026
12:11 PM
AGIOAgios

Agios: pre-sNDA FDA meeting for mitapivat in sickle cell disease set for Q1 2026

The press release states that Agios will hold a pre-sNDA meeting with the FDA in Q1 2026 for mitapivat in sickle cell disease, after which the company plans to submit a U.S. marketing application. This sets the next regulatory milestone for the sickle cell indication following the November 2025 topline readout.

PDUFA date setSEC 8-KOpen record
Oct 30, 2025
10:32 AM
AGIOAgios

Agios: FDA extends PYRUKYND thalassemia sNDA PDUFA to Dec 7, 2025

FDA extended the PDUFA goal date for the PYRUKYND sNDA in thalassemia by three months to December 7, 2025 after requesting a REMS for potential hepatocellular injury risk. The extension was not due to new efficacy or safety data; the application remains under active FDA review with U.S. launch preparations ongoing.

PDUFA date extendedSEC 8-KOpen record

Peers by market cap

Companies in the same sector closest to AGIO in market value.

AGIO FDA Calendar & Catalysts — Agios | Biopharma · FDA Approvals | SimianX AI